TSHA Q4 2024 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-43.9% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$20M-985.8% margin

Net Income

-$19M-929.0% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+13.1%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$160M

Total Liabilities

$89M

Stockholders' Equity

$72M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$4M	-43.9%
Gross Profit	$2M	$4M	-43.9%
Operating Income	-$20M	-$16M	-22.7%
Net Income	-$19M	$48M	-139.3%